Prime Medicine, Inc. (PRME)
NASDAQ:PRME
Want to see PRME full AI Analyst Report?
PRME Stock Chart & Stats
$3.81
-$0.14(-4.27%)
At close: 4:00 PM EST
$3.81
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$1.11 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)2.23M
Market Cap
$615.68M
Enterprise Value$669.08M
Total Cash (Recent Filing)$177.68M
Total Debt (Recent Filing)$116.43M
Price to Earnings (P/E)―
Beta2.89
Next Earnings
May 07, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding180,552,190
10 Day Avg. Volume1,827,493
30 Day Avg. Volume2,225,888
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue144.45
Enterprise Value/Gross Profit-248.82
Enterprise Value/Ebitda-3.42
Forecast
1Y Price Target
$5.50Price Target Upside44.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$20.60M
Bulls Say, Bears Say
Bulls Say
Delivery Platform SafetyThe GalNAc-LNP delivery approach used for prime editing is viewed as less likely to trigger the immune responses seen with viral vectors, indicating a potential safety and tolerability advantage.
Preclinical EfficacyHigh levels of liver cell correction and rapid normalization of liver copper observed with prime editing in animal models suggest strong biological activity that may translate into human benefit.
Regulatory PathwayAnalyst reports management is engaging with the FDA and believes existing clinical data for PM359 could support an accelerated approval pathway and a biologics license application.
Bears Say
Competitive LandscapeAn increasingly crowded therapeutic landscape for alpha-1 antitrypsin deficiency could intensify competition and limit the company's potential market share for its AATD program.
Financial RunwayAnalyst warns that high cash burn and a limited cash runway create funding risk that could pressure operations and require dilutive financing.
Legal And Sector RiskAnalyst maintains a neutral stance due to lack of near-term meaningful catalysts, ongoing legal uncertainty, and heightened volatility in the gene editing sector that could weigh on the stock.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $615.68M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is May 07, 2026 which is in 2 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Mar 03, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.047.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 180,552,190 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -9.227%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (44.36% Upside)
$5.50 (44.36% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 6.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
207.25%
12-Months-Change
Fundamentals
Return on Equity
-178.61%
Trailing 12-Months
Asset Growth
25.81%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$5.50
▲(44.36% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
49.23% Insiders
6.99% Mutual Funds
2.53% Other Institutional Investors
28.92% Public Companies and
Individual Investors